VI
HRMY icon

Versor Investments’s Harmony Biosciences HRMY Stock Holding History

Versor Investments’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,423
Closed -$1.14M – 299
2025
Q4 		$1.14M Buy
30,423
+10,529
+53% +$346K 0.18% 111
2025
Q3 		$548K Buy
19,894
+894
+5% +$30.8K 0.1% 287
2025
Q2 		$600K Buy
+19,000
New +$611K 0.11% 325
2024
Q4 		– Sell
-14,284
Closed -$571K – 853
2024
Q3 		$571K Sell
14,284
-3,926
-22% -$138K 0.09% 371
2024
Q2 		$549K Buy
+18,210
New +$548K 0.1% 328
2024
Q1 		– Sell
-10,661
Closed -$344K – 776
2023
Q4 		$344K Buy
10,661
+2,850
+36% +$79.5K 0.07% 478
2023
Q3 		$256K Buy
7,811
+871
+13% +$30.2K 0.05% 527
2023
Q2 		$244K Sell
6,940
-2,509
-27% -$86.6K 0.04% 496
2023
Q1 		$309K Buy
9,449
+4,599
+95% +$209K 0.04% 486
2022
Q4 		$267K Buy
+4,850
New +$267K 0.02% 552

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Versor Investments's HRMY Position: Q1 2026 in Review

Versor Investments sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 30,423 shares — an estimated $1.14M sold.

Versor Investments first reported a position in HRMY in Q4 2022 and held it in 10 quarters. The position peaked at $1.14M in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Versor Investments reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Versor Investments sold 30,423 Harmony Biosciences shares in Q1 2026, an estimated $1.14M.
  • Versor Investments first reported a position in Harmony Biosciences in Q4 2022 and held it in 10 quarters.
  • Versor Investments's Harmony Biosciences position peaked at $1.14M in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Versor Investments's 13F filing for Q1 2026, filed 12 May 2026.